⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248125 | 0.72 | — | — | |
| SCHEMBL1503 | 0.71 | — | — | |
| SCHEMBL30802139 | 0.69 | — | — | |
| SCHEMBL28959328 | 0.69 | HCAR2 (0.44) | — | |
| Ammonia Solution, Strong SCHEMBL28254978 | 0.69 | — | — | |
| SCHEMBL29150915 | 0.69 | — | — | |
| SCHEMBL30404482 | 0.69 | — | — | |
| Potassium SCHEMBL30471622 | 0.69 | — | — | |
| SCHEMBL28852463 | 0.69 | HCAR2 (0.44) | — | |
| Methane SCHEMBL28055339 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025059366-A1 | RAS INHIBITORS | KUMQUAT BIOSCIENCES INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4359081-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-4344702-A2 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| WO-2024050020-A1 | INVARIANT NATURAL KILLER T-CELL ACTIVATORS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4076662-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011050160-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008013622-A2 | FUNGICIDAL AZOCYCLIC AMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-01-31 | — | — | WO | disclosed |
| CN-1913898-A | Substituted piperazines | CHEMOCENTRYX INC (US) | 2007-02-14 | — | — | CN | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |